The trial of HepTcell is intended for the treatment of patients with chronic hepatitis B. Credit: Nephron/commons.wikimedia.org.

Clinical-stage biopharmaceutical company Altimmune has completed enroling patients for its Phase II clinical trial of HepTcell for the treatment in patients with chronic hepatitis B (CHB).

The multicentre trial enroled nearly 80 subjects who were randomised into 1:1 ratio to HepTcell or placebo.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Subjects with inactive CHB and low hepatitis B surface antigen (HBsAg) levels participated in the study.

Clinical response, defined as a 1-log or greater reduction in HBsAg, is measured as primary endpoint, while changes in the levels of hepatitis B virus (HBV) DNA, pre-genomic RNA and other virologic response markers are considered as secondary endpoints of the trial.

The company is conducting HepTcell Phase II trial in 26 sites in North America, Europe and Southeast Asia.

See Also:

Altimmune CEO and president Vipin Garg said: “We are pleased to have achieved this milestone in the HepTcell Phase II trial and look forward to the data readout in Q1 2024.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“In addition, we look forward to initiating our Phase IIb biopsy non-alcoholic steatohepatitis (NASH) trial in mid-2023 and announcing topline data from our 48-week MOMENTUM obesity trial in the fourth quarter of 2023.”

HepTcell, an immunotherapeutic, consists of nine synthetic peptides representing conserved HBV sequences adjuvanted with Valneva’s TLR9-based adjuvant, IC31.

The company develops new peptide-based therapeutics to treat liver diseases and obesity.

It is also developing pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and NASH.